Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown aetiology, may offer strategic insights into IPF drug development that are similarly applicable to other indications. In this blog we look at the adoption and cost-effectiveness of two approved IPF therapies, nintedanib and pirfenidone, and […]
We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.
We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.
We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.
